Some of the biggest names in longevity research — and at least one Seattle biotech startup — say they’ll enter a $101 million, seven-year competition to turn back the clock… Read More
Epigenetics, aging and microbial evolution: Those are the latest words in biomedical research for the Paul G. Allen Frontiers Group, backed up with $7.5 million in awards for five teams… Read More
The way BioViva founder Elizabeth Parrish sees it, biological aging is a disease – and she’s willing to bet her life on a cure. Last fall, the 45-year-old Seattle-area woman underwent an experimental type… Read More